Physicochemical characterization of efavirenz-cyclodextrin inclusion complexes

AAPS PharmSciTech

Volumn 10, Issue 1, 2009, Pages 81-87

  Sathigari, Sateeshkumar ^a   Chadha, Gurkishan ^a   Lee, Y H Phillip ^a   Wright, Nydeia ^b   Parsons, Daniel L ^a   Rangari, Vijay K ^b   Fasina, Oladiran ^c   Babu, R Jayachandra ^a  

^a AUBURN UNIVERSITY   (United States)

^b TUSKEGEE UNIVERSITY   (United States)

^c AUBURN UNIVERSITY   (United States)

Author keywords

Cyclodextrins; Dissolution rate; Efavirenz; Inclusion complexes; Solubility

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; EFAVIRENZ; METHYL BETA CYCLODEXTRIN; WATER; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BENZOXAZINE DERIVATIVE; BETA CYCLODEXTRIN DERIVATIVE; DRUG CARRIER; METHYL-BETA-CYCLODEXTRIN; PROTEINASE INHIBITOR;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DETERMINATION; DRUG FORMULATION; DRUG MIXTURE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FREEZE DRYING; INTERMETHOD COMPARISON; PHYSICAL CHEMISTRY; PHYSICAL PHASE; SCANNING ELECTRON MICROSCOPY; X RAY DIFFRACTION; CHEMISTRY; KINETICS; METHODOLOGY; PHARMACEUTICS; SOLUBILITY; X RAY CRYSTALLOGRAPHY;

BENZOXAZINES; BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CHEMISTRY, PHARMACEUTICAL; CRYSTALLOGRAPHY, X-RAY; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; FREEZE DRYING; HIV PROTEASE INHIBITORS; KINETICS; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 67549107666     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-008-9180-3     Document Type: Article

References (26)

1. M. B. Maurin, S. M. Rowe, K. Blom, and M. E. Pierce. Kinetics and mechanism of hydrolysis of efavirenz. Pharm. Res. 19:517-522 (2002).
2. S. M. Bahal, J. M. Romansky, and F. J. Alvarez. Medium chain triglycerides as vehicle for palatable oral liquids. Pharm. Dev. Technol. 8:111-115 (2003).
3. N. A. Kasim, M. Whitehouse, C. Ramachandran, M. Bermejo, H. Lennernaes, A. S. Hussain, H. E. Junginger, S. A. Stavchansky, K. K. Midha, V. P. Shah, and G. L. Amidon. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol. Pharm. 1:85-96 (2004).
4. R. Takano, K. Sugano, A. Higashida, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita. Oral absorption of poorly water-soluble drugs: Computer simulation of fraction absorbed in humans from a miniscale dissolution test. Pharm. Res. 23:1144-1156 (2006).
5. B. J. Aungst, N. H. Nguyen, N. J. Taylor, and D. S. Bindra. Formulation and food effects on the oral absorption of a poorly water soluble, highly permeable antiretroviral agent. J. Pharm. Sci. 91:1390-1395 (2002).
6. S. A. Kaplan. Biopharmaceutical considerations in drug formulation design and evaluation. Drug Metab. Rev. 1:15-34 (1972).
7. V. P. Shah. The role of dissolution testing in the regulation of pharmaceuticals: The FDA perspective. Pharm. Dissolution Test. 81-96 (2005).
8. D. E. Walton, and C. J. Mumford. Spray dried products - characterization of particle morphology. Chem. Eng. Res. Des. 77:21-38 (1999).
9. O. D. S. Viana, J. Benigno Junior, R. M. F. Silva, F. P. Morais de Medeiros, S. Grangeiro Junior, M. Muniz de Albuquerque, and P. J. Rolim Neto. Development of formulations and technology for obtaining of efavirenz coated tablets - anti-HIV therapy. Rev. Bras. Cienc. Farm. 42:505-511 (2006).
10. J. Z. Gao, M. A. Hussain, R. Motheram, D. A. B. Gray, I. H. Benedek, W. D. Fiske, W. J. Doll, E. Sandefer, R. C. Page, and G. A. Digenis. Investigation of human pharmacoscintigraphic behavior of two tablets and a capsule formulation of a high dose, poorly water soluble/highly permeable drug (efavirenz). J. Pharm. Sci. 96:2970-2977 (2007).
11. M. E. Brewster, and T. Loftsson. Cyclodextrins as pharmaceutical solubilizers. Adv. Drug Delivery Rev. 59:645-666 (2007).
12. J. Szejtli, and L. Szente. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur. J. Pharm. Biopharm. 61:115-125 (2005).
13. R. Challa, A. Ahuja, J. Ali, and R. K. Khar. Cyclodextrins in drug delivery: An updated review. AAPS PharmSciTech. 6:E329-357 (2005).
14. T. Higuchi, and K. A. Connors. Phase-solubility techniques. Advan. Anal. Chem. Instr. 4: 117-212 (1965).
15. K. A. Khan, and C. T. Rhodes. Effect of compaction pressure on the dissolution efficiency of direct compression systems. Pharm. Acta Helv. 49:258-261 (1974).
16. K. Rajendrakumar, S. Madhusudan, and T. Pralhad. Cyclodextrin complexes of valdecoxib: Properties and anti-inflammatory activity in rat. Eur. J. Pharm. Biopharm. 60:39-46 (2005).
17. P. Mura, N. Zerrouk, M. T. Faucci, F. Maestrelli, and C. Chemtob. Comparative study of ibuproxam complexation with amorphous beta-cyclodextrin derivatives in solution and in the solid state. Eur. J. Pharm. Biopharm. 54:181-191 (2002).
18. L. A. Miller, R. L. Carrier, and I. Ahmed. Practical considerations in development of solid dosage forms that contain cyclodextrin. J. Pharm. Sci. 96:1691-1707 (2007).
19. G. Zingone, and F. Rubessa. Preformulation study of the inclusion complex warfarin-beta-cyclodextrin. Int. J. Pharm. 291:3-10 (2005).
20. A. Figueiras, R. A. Carvalho, L. Ribeiro, J. J. Torres-Labandeira, and F. J. B. Veiga. Solid-state characterization and dissolution profiles of the inclusion complexes of omeprazole with native and chemically modified beta-cyclodextrin. Eur. J. Pharm. Biopharm. 67:531-539 (2007).
21. V. R. Sinha, R. Anitha, S. Ghosh, A. Nanda, and R. Kumria. Complexation of celecoxib with beta-cyclodextrin: Characterization of the interaction in solution and in solid state. J. Pharm. Sci. 94:676-687 (2005).
22. R. L. Carrier, L. A. Miller, and I. Ahmed. The utility of cyclodextrins for enhancing oral bioavailability. J. Controlled Release. 123:78-99 (2007).
23. S. Baboota, M. Dhaliwal, and K. Kohli. Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. Preparation and properties of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: A technical note. AAPS PharmSciTech. 6:E83-90 (2005).
24. O. I. Corrigan, and C. T. Stanley. Mechanism of drug dissolution rate enhancement from beta-cyclodextrin-drug systems. J. Pharm. Pharmacol. 34:621-626 (1982).
25. G. Dollo, P. Le Corre, M. Chollet, F. Chevanne, M. Bertault, J. L. Burgot, and R. Le Verge. Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with beta-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives. J. Pharm. Sci. 88:889-895 (1999).
26. Y.H. Lee, and R.J. Babu. Enhancement of solubility and dissolution rate of Gefitinib by complexation with cyclodextrins. Contributed poster; 28th Annual meeting of the Graduate Research Association of Students in Pharmacy, Tallahassee, FL, USA; 6/6-8/08.